Editas Medicine Company Profile (NASDAQ:EDIT)

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Editas Medicine, Inc. (NASDAQ:EDIT) posted its quarterly earnings results on Monday, May, 15th. The company reported ($0.85) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.23. The company had revenue of $0.68 million for the quarter, compared to the consensus estimate of $1 million. Editas Medicine had a negative net margin of 1,864.00% and a negative return on equity of 63.29%. The business's revenue was down 16.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.80) EPS. View Editas Medicine's Earnings History.

7 analysts have issued twelve-month target prices for Editas Medicine's shares. Their predictions range from $17.00 to $35.00. On average, they anticipate Editas Medicine's stock price to reach $28.00 in the next year. View Analyst Ratings for Editas Medicine.

Here are some recent quotes from research analysts about Editas Medicine stock:

• 1. According to Zacks Investment Research, "Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. " (7/18/2017)
• 2. Cann analysts commented, "We are initiating coverage of Editas Medicine, a development-stage biotechnology platform company, with a Perform rating. Editas is developing gene editing therapies for the treatment of various human diseases. Its gene editing system, CRISPR, utilizes short sequences of RNA to guide a DNA cutting enzyme (DNA nuclease) to cut specific sequences of DNA. We anticipate Editas Medicine will continue to form collaborations for its CRISPR technology and advance its current collaborations into later stages of development." (7/17/2017)
• 3. Chardan Capital analysts commented, "We initiate coverage of Editas Medicine (EDIT) with a Buy rating (PT $65), on our view of the company's IP breadth and strength providing significant upside potential for shares, via both internal and partnered program opportunities. Editas is a preclinical biotech company aiming to treat various genetic conditions through the CRISPR gene editing system, in which a CRISPR guide RNA (gRNA) delivers a nuclease (a sort of "DNA scissors") to specifically modify a particular DNA sequence to treat diseases. Editas' lead asset, targeting Leber's congenital amaurosis type 10 (LCA10), could be one of the first CRISPR therapies to enter the clinic. An IND filing is expected by year-end 2017." (3/27/2017)
• 4. Cowen and Company analysts commented, "Today Editas partnered its ophthalmology CRISPR programs with Allergan for $90MM." (3/15/2017)
• 5. Jefferies Group LLC analysts commented, "We gained incremental color on IP and pipeline progress from our meeting. Mgmt continues to be confident about their broad IP portfolio, which allows them to be prepared for any possible outcome from ongoing interference proceedings. The LCA10 IND filing remains on track by YE17 and likely would require a RAC meeting. Mgmt laid out key elements for the IND filing package and expect to present NHP data at medical meetings in 2017." (2/15/2017)

Some companies that are related to Editas Medicine include Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Momenta Pharmaceuticals (MNTA), Medpace Holdings (MEDP), Genomic Health (GHDX), Esperion Therapeutics (ESPR), Genus plc (GNS), Immunomedics (IMMU), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Cellectis S.A. (CLLS), Albany Molecular Research (AMRI), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA), Crispr Theraptc (CRSP), Spectrum Pharmaceuticals (SPPI) and Intellia Therapeutics (NTLA).

Editas Medicine's management team includes the folowing people:

• Katrine S. Bosley, President, Chief Executive Officer, Director
• Andrew A. F. Hack, Chief Financial Officer
• Charles Albright, Chief Scientific Officer
• Gerald Cox, Chief Medical Officer
• Andrew Hirsch, Director
• Akshay K. Vaishnaw M.D., Ph.D., Director
• Kevin J. Bitterman Ph.D., Independent Director
• Alexis Borisy, Independent Director
• Douglas G. Cole M.D., Independent Director

(EDIT) raised $100 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

Editas Medicine's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Nisa Investment Advisors LLC (0.19%), Fox Run Management L.L.C. (0.08%), First American Bank (0.04%), Hershey Trust Co. (0.04%) and Creative Planning (0.02%). Company insiders that own Editas Medicine stock include Alexandra Glucksmann, Andrew A F Hack, Boris Nikolic, Gerald Frank Cox, James E Flynn, Kevin Bitterman, Kevin P Starr and Polaris Venture Management Co. View Institutional Ownership Trends for Editas Medicine.

Editas Medicine's stock was bought by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Fox Run Management L.L.C., First American Bank, Hershey Trust Co. and Creative Planning. Company insiders that have bought Editas Medicine stock in the last two years include Boris Nikolic, Gerald Frank Cox and James E Flynn. View Insider Buying and Selling for Editas Medicine.

Shares of Editas Medicine can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Editas Medicine stock can currently be purchased for approximately $15.88.